In glucocorticoid-dependent polymyalgia rheumatica, tocilizumab improved a composite clinical outcome at 24 wk

David S Pisetsky

doi:10.7326/J22-0107

In glucocorticoid-dependent polymyalgia rheumatica, tocilizumab improved a composite clinical outcome at 24 wk

Ann Intern Med. 2023 Jan;176(1):JC5. doi: 10.7326/J22-0107. Epub 2023 Jan 3.

Author

David S Pisetsky¹

Affiliation

¹ University Medical Center, Durham, North Carolina, USA (D.S.P.).

PMID: 36592464
DOI: 10.7326/J22-0107

Abstract

Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, et al. Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial. JAMA. 2022;328:1053-62. 36125471.

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Giant Cell Arteritis* / chemically induced
Giant Cell Arteritis* / drug therapy
Glucocorticoids / therapeutic use
Humans
Polymyalgia Rheumatica* / drug therapy
Randomized Controlled Trials as Topic

Substances

Antibodies, Monoclonal, Humanized
Glucocorticoids
tocilizumab